TransMedics Group, Inc. (NASDAQ:TMDX) Stake Boosted by Montanaro Asset Management Ltd

Montanaro Asset Management Ltd increased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 12.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 117,235 shares of the company's stock after purchasing an additional 12,985 shares during the period. TransMedics Group accounts for 3.3% of Montanaro Asset Management Ltd's investment portfolio, making the stock its 12th biggest position. Montanaro Asset Management Ltd owned about 0.35% of TransMedics Group worth $18,364,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State of Alaska Department of Revenue purchased a new stake in shares of TransMedics Group in the third quarter valued at $2,560,000. Allspring Global Investments Holdings LLC boosted its holdings in TransMedics Group by 5.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company's stock valued at $94,061,000 after acquiring an additional 30,092 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in TransMedics Group in the second quarter valued at $1,400,000. Handelsbanken Fonder AB boosted its holdings in TransMedics Group by 657.6% in the third quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company's stock valued at $10,111,000 after acquiring an additional 55,900 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in TransMedics Group by 337,462.5% in the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company's stock valued at $1,997,000 after acquiring an additional 26,997 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TMDX. Baird R W upgraded TransMedics Group to a "strong-buy" rating in a report on Tuesday, September 24th. Stephens lifted their target price on TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Morgan Stanley lifted their target price on TransMedics Group from $104.00 to $145.00 and gave the company an "equal weight" rating in a report on Monday, July 15th. Canaccord Genuity Group reduced their price objective on TransMedics Group from $169.00 to $109.00 and set a "buy" rating on the stock in a research note on Tuesday, October 29th. Finally, Robert W. Baird reduced their price objective on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of "Buy" and a consensus price target of $144.80.

Insider Activity at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of the business's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares of the company's stock, valued at $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Tamer I. Khayal sold 2,958 shares of the business's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares of the company's stock, valued at $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,958 shares of company stock valued at $5,230,528 over the last three months. 7.00% of the stock is owned by insiders.

TransMedics Group Stock Up 0.6 %

Shares of NASDAQ TMDX traded up $0.48 during midday trading on Friday, reaching $85.98. 1,248,860 shares of the company's stock were exchanged, compared to its average volume of 2,090,369. TransMedics Group, Inc. has a 52-week low of $55.29 and a 52-week high of $177.37. The stock has a market capitalization of $2.89 billion, a PE ratio of 91.47 and a beta of 2.08. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business's fifty day moving average price is $132.03 and its two-hundred day moving average price is $139.54.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to analysts' expectations of $115.00 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The firm's revenue was up 63.7% compared to the same quarter last year. Analysts forecast that TransMedics Group, Inc. will post 1.07 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.